pcDNA-RELΔ424-490
(Plasmid
#27267)
-
Depositing Lab
-
Sequence Information
Full plasmid sequence is not available for this item.
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 27267 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepcDNA3.1(-)
-
Backbone manufacturerInvitrogen
- Backbone size w/o insert (bp) 5400
-
Vector typeMammalian Expression
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameREL
-
Alt nameRELdeltaTAD1
-
SpeciesH. sapiens (human)
-
Insert Size (bp)1563
-
MutationDeletion of transactivation domain I (aa 425-490)
-
Entrez GeneREL (a.k.a. C-Rel, HIVEN86A, IMD92)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site XbaI (not destroyed)
- 3′ cloning site HindIII (not destroyed)
- 5′ sequencing primer T7
- 3′ sequencing primer BGH-Rev (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
Please note that Addgene's sequencing results confirmed N424 is present in the REL sequence. Despite the plasmid name, amino acids 425-490 of REL have been deleted. This plasmid is exactly as created by the depositing laboratory and as described in the associated publication listed below and in Chin et al., Oncogene. 2009 May 21;28(20):2100-11.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pcDNA-RELΔ424-490 was a gift from Thomas Gilmore (Addgene plasmid # 27267 ; http://n2t.net/addgene:27267 ; RRID:Addgene_27267) -
For your References section:
Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL's in vitro transforming activity. Starczynowski DT, Trautmann H, Pott C, Harder L, Arnold N, Africa JA, Leeman JR, Siebert R, Gilmore TD. Oncogene. 2007 Apr 26. 26(19):2685-94. 10.1038/sj.onc.1210089 PubMed 17072339